Summary Chronic inflammation is associated with 25% of all cancers. In the inflammation-cancer axis, prostaglandin E 2 (PGE 2 ) is one of the major players. PGE 2 synthases (PGES) are the enzymes downstream of the cyclooxygenases (COXs) in the PGE 2 biosynthesis pathway. Microsomal prostaglandin E 2 synthase 1 (mPGES-1) is inducible by pro-inflammatory stimuli and constitutively expressed in a variety of cancers. The potential role for this enzyme in tumorigenesis has been reported and mPGES-1 represents a novel therapeutic target for cancers. In order to identify novel small molecule inhibitors of mPGES-1, we screened the ChemBridge library and identified 13 compounds as potential hits. These compounds were tested for their ability to bind directly to the enzyme using surface plasmon resonance spectroscopy and to decrease cytokine-stimulated PGE 2 production in various cancer cell lines. We demonstrate that the compound PGE0001 (ChemBridge ID number 5654455) binds to human mPGES-1 recombinant protein with good affinity (K D =21.3±7.8 μM). PGE0001 reduces IL-1β-induced PGE 2 release in human HCA-7 colon and A549 lung cancer cell lines with EC 50 in the sub-micromolar range. Although PGE0001 may have alternative targets based on the results from in vitro assays, it shows promising effects in vivo. PGE0001 exhibits significant anti-tumor activity in SW837 rectum and A549 lung cancer xenografts in SCID mice. Single injection i.p. of PGE0001 at 100 mg/kg decreases serum PGE 2 levels in mice within 5 h. In summary, our data suggest that the identified compound PGE0001 exerts antitumor activity via the inhibition of the PGE 2 synthesis pathway.
Introduction
Prostaglandin E 2 (PGE 2 ), a key mediator of inflammation, is the most abundant prostanoid with various bioactivities and has been associated with numerous pathologies [1, 2] . Thus, inhibition of PGE 2 synthesis and its action has been suggested in the treatment of inflammatory-associated diseases, including cancer [2] . PGE 2 is synthesized sequentially by the following three enzymatic reactions. Upon the stimulation of IL-1β, for example, membrane-bound and secretory phospholipase A 2 (PLA 2 ) isoforms release arachidonic acid (AA) from membrane phospholipids [3] . Next, the cyclooxygenases (COX-1 and COX-2) convert AA into the unstable intermediate, prostaglandin endoperoxide PGH 2 . Finally, PGE 2 synthases (PGESs) isomerize PGH 2 into PGE 2 . Elevated levels of PGE 2 and COX-2, which catalyze the rate-limiting step in PGE 2 biosynthesis, are often observed in human cancers such as colon cancer [4, 5] . Therefore, COX-2 inhibitors have been tested in humans and pre-clinical models for the prevention or treatment of colon cancer [6, 7] . However, inhibition of COXs may lead to cardiotoxicity due to the global reduction of other key prostaglandins, and imbalanced production of pro-thrombotic eicosanoids (e.g. increased thromboxane A 2 ) and antithrombotic eicosanoids (e.g. decreased prostaglandin I 2 , PGI 2 ) [8, 9] . Therefore, developing inhibitors downstream COXs could represent an alternative therapeutic strategy with potentially less side effects [10, 11] .
Three PGES isoforms have been cloned [12] [13] [14] . The expression and activity of microsomal PGE 2 synthase-1, (mPGES-1), is induced by various inflammatory stimuli such as pro-inflammatory cytokines IL-1β and TNF-α [12, 15] , whereas mPGES-2 (microsomal PGE 2 synthase-2) and cPGES (cytosolic PGE 2 synthase) are constitutively expressed and active [13, 14] . Interestingly, only constitutive over-expression of mPGES-1 has been reported in cancers including colon, lung, gastric, ovarian, pancreatic, and breast cancers [16] [17] [18] [19] [20] [21] [22] , suggesting its tumorigenic potential. Indeed, the role of mPGES-1 in tumorigenesis has been shown by both transplantation tumor models [18, 23, 24] and genetic deletion approaches [23, 25] . Given the known effects of prostaglandins on cardiovascular function and the recent history of secondary effects associated with high doses of COX-2 specific inhibitors [8, 26] , there are legitimate concerns regarding the potential cardiotoxicity risks for any new inhibitors of the prostaglandin biosynthesis pathway. However, it was recently reported by Cheng et al. [27] that the deletion of mPGES-1, unlike deletion, disruption, or inhibition of COX-2, did not result in hypertension or a predisposition to thrombosis in normolipidemic mice. This important finding suggests that selective mPGES-1 inhibitors would have very low if any cardiotoxic side effects typically associated with COX-2 inhibitors.
Recently, some compounds have been described to inhibit mPGES-1 activity, but none have been developed as anticancer agents in vivo [28] . There are several examples of compounds that were initially developed to target the COX-2 but that were shown later to also inhibit mPGES-1. For example, NS-398 [2-cyclohexyloxy-4-nitrophenyl)-methanesulfonamide], developed in Japan as an arylsulfonamide derivative of the anti-inflammatory agent nimesulide [29] , is a COX-2 inhibitor that inhibits mPGES-1 with an IC 50 of 20 μM in vitro [30] . In animal models, NS-398 was a potent antiinflammatory agent [31, 32] ; however, it had poor bioavailability and produced hepatotoxic metabolites. Thus, NS-398 was not developed into a therapeutic agent. Recently, a series of indole compounds showed selectivity and higher activity against the inducible mPGES-1 with the lowest IC 50 value found being 3 nM [33] . However, due to a high degree of protein binding and poor cell permeability, these series of compounds loose potency in cell-based assays and, to our knowledge, have not been tested in vivo. Finally, licofelone and a number of natural compounds were also recently found to inhibit mPGES-1 activity in the low micromolar range [34] [35] [36] [37] , but many of them also affected COX activity or expression.
Herein, we generated a pharmacophore query using the structure of triclosan, an anti-inflammatory compound sharing pharmacophore features with NS-398. The anti-inflammatory property of triclosan has been attributed in part to the inhibition of PGE 2 biosynthesis. The molecular docking model of triclosan within the mPGES-1 active site has also been described [28] . This query was used to perform Unity-based three dimensional searches on the ChemBridge diversity library to identify thirteen compounds. Using surface plasmon resonance (SPR) spectroscopy, we confirmed the binding of several compounds to human recombinant mPGES-1 which correlated with the inhibition of IL-1β-induced PGE 2 production in colon and lung cancer cells. In this report, we show that one of these compounds, ChemBridge 5654455 (hereafter referred to as "PGE0001") exhibited good cellular activity in colorectal and lung cancer cells and promising anti-tumor activities in their corresponding subcutaneous xenograft mouse models with appropriate pharmacokinetic properties.
Materials and methods

Compounds and reagents
Compounds ID 5654455, 5933870, 6795274, 7384071, 7418129, 7786927, 7882458, 5662444, 5807166, 5935487, 5724933, 6239316, and 5862295 were purchased from ChemBridge Corp. (San Diego, CA). Anti-COX-2 monoclonal antibody (mAb) (clone CX229), anti-mPGES-1 mAb (clone C6C), anti-mPGES-2 polyclonal antibody (pAb), and anticPGES pAb were all purchased from Cayman Chemical (Ann Arbor, MI). Anti-β-actin mAb was purchased from SigmaAldrich (St. Louis, MO). Reduced L-glutamine (GSH) was purchased from Sigma-Aldrich. Recombinant human mPGES-1 was purchased from Cayman Chemical. Recombinant Human IL-1β was purchased from R&D Systems (Minneapolis, MN). Prostaglandin H 2 was purchased from Enzo Life Sciences (Plymouth Meeting, PA). Sphingosine kinase (SPHK-1) inhibitor 2 and compound MK-886 were both purchased from Cayman Chemical. Celecoxib was purchased from LKT Laboratories (St. Paul, MN).
Molecular modeling procedure
Docking was performed using the Sybyl 8.0 modeling software package from Tripos Inc (St Louis, MS). The crystal structure of mPGES-1 (PDB code: 3dww) was used for all docking protocols. The protein structure along with the active site and different ligands were used as inputs. 
Bacterial expression of human mPGES-1
The 6xHis-tagged human mPGES-1 was expressed from the pET30(b) vector in E. coli BL21(DE3) cells. An overnight culture of BL21(DE3) cells in LB broth containing kanamycin (50 μg/ml) was diluted 1:100 into LB broth containing kanamycin. The culture was grown at 37°C with shaking (250 rpm) until the A 600 nm was around 0.6. Expression of 6xHis-mPGES-1 was then induced by the addition of 0.5 mM IPTG, and the culture was grown for another 3 h at 37°C with shaking. The cell pellets were harvested by centrifugation (5,000 × g, 10 min at 4°C) and stored at −80°C for further purification.
Bacterial membrane preparation and purification of 6xHis-mPGES-1 Preparation of membranes was performed by following the procedure from Thoren et al. [38] . The supernatant of the membrane preparation was loaded onto a Ni-NTA (Qiagen, Valencia, CA) chromatography column equilibrated with binding buffer containing 15 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 0.2% Triton X-100, and 1 mM GSH, then washed with washing buffer (60 mM imidazole in binding buffer). The bound protein was then eluted with elution buffer (250 mM imidazole in binding buffer). The eluted peak was immediately desalted into 20 mM sodium phosphate buffer, pH 7.5, 50 mM NaCl, 2.5 mM GSH, and 0.2% reduced Triton X-100, using Zeba Spin Desalting Columns, 7 K MWCO (Thermo Scientific, Rockford, IL).
Surface plasmon resonance (SPR) spectroscopy binding assays All interaction analyses were performed with a Biacore 2000, Biacore 2000 Control Software v. 3.2, and BIAevaluation v. 4.1 analysis software (Biacore, Piscataway, NJ) as already described in reference [39] . His-tagged mPGES-1 fusion protein was immobilized on a CM5 sensorchip (Biacore BR-1000-12) using Biacore's Amine Coupling Kit (Biacore BR-1000-50) to a level of 10,000 Response units (RUs). Small molecule analytes at concentrations ranging from one tenth to ten times the predicted K D were injected at a high flow rate (50 μl/min). Dimethylsulfoxide (DMSO) concentrations in all samples and running buffer were 2% (v/v). K D s were calculated using a 1:1 Langmuir model.
Cell culture and Western blots
Colorectal cancer cell lines SW480, SW620, SW837, HCT-116, HT-29, HCA-7, and A549 lung cancer cells were obtained from the American Tissue Type Culture Collection (ATCC). HT-29 and HCT-116 were maintained in McCoy's 5A from Cellgro (Herndon, VA) and cultured at 37°C and 5% CO 2 . HCA-7 and A549 were maintained in Dulbecco's Modified Eagle's Medium (DMEM) from Cellgro and cultured at 37°C and 5% CO 2 . SW837, SW480 and SW620 were maintained in Leibovitz's L-15 from ATCC (Manassas, VA) and cultured at 37°C without CO 2 as instructed by the ATCC. All media were supplemented with 10% FBS from Gemini Bio-Products (Sacramento, CA) and 1x Penicillin-Streptomycin-Glutamine from Gibco (Grand Island, NY). Following treatments, cells were harvested and lysed in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 20% SDS) supplemented with Protease Inhibitor Cocktail (Sigma-Aldrich), 0.4 mM PMSF (Sigma-Aldrich), 1 mM sodium orthovanadate (Sigma-Aldrich), 1 mM sodium fluoride (Sigma-Aldrich), and 1 mM sodium phosphate (Sigma-Aldrich). A 40 μg quantity of proteins (quantified using Bradford Reagent from Bio-Rad, Hercules, CA) were loaded onto 10% NuPage gels from Invitrogen (Carlsbad, CA). The proteins were electrophoretically transferred onto PVDF membranes (PerkinElmer, Waltham, MA). The membranes were blocked and incubated with primary antibodies according to the product instructions sheet. Proteins were visualized by ECL reagents from Perkin-Elmer, and exposed to HyBlot CL films from Denville Scientific (Metuchen, NJ).
PGE 2 production
Cells were seeded in 6-well plates and incubated overnight in DMEM/10% FBS. They were serum starved for the next 18 h. Cells were then treated with 10 ng/ml IL-1β and increasing concentration of compounds (dissolved in DMSO) in 1 ml serum-free medium. After 72 h incubation, the supernatants were collected for PGE 2 level detection using the PGE 2 EIA kit (R&D Systems).
PGE 2 de novo synthesis assay
The assay was performed as described in reference [40] with some modification. Non-stimulated HCA-7 or A549 stimulated with IL-1β for 24 h were seeded in the 6-well plates and incubated overnight. Cells were then treated with serum-free DMEM containing vehicle (1% DMSO) or compounds dissolved in the same vehicle (i.e., 1% DMSO) for 2 h, and with 10 μM arachidonic acid (Cayman Chemical) for another 10 min, at 37°C and 5% CO 2 . The PGE 2 and 6-keto PGF 1α levels in the conditioned media were then determined using the respective EIA kits (from R&D Systems and Cayman Chemical).
mPGES-1, COX-2, and SPHK-1 cell-free assays
In vitro mPGES-1 activity assay was performed following protocols below. Briefly, mPGES-1 recombinant protein (purchased from Cayman Chemical or purified as described above) or the membrane fraction of IL-1β-stimulated A549 [30] was diluted in a reaction buffer containing 0.1 M sodium phosphate buffer, pH 7.4, 0.3% TritonX-100, 1 mM EDTA, and 2.5 mM GSH. Compounds were then added to the solution to a final concentration of 20 μM. After 2 h incubation at room temperature, the reaction was started by adding cold PGH 2 to a final concentration of 10 μM. The reaction was terminated immediately after 1.5 min by stop solution consisting of 20 mM FeCl 2 . Solution in each sample was diluted 30 times for measurement of PGE 2 concentrations by an EIA kit (R&D Systems). Sphingosine kinase-1 (SPHK-1) activity assay was measured using a SPHK-1 inhibitor screening assay kit (Cayman Chemical) following manufacturer's instructions. COX-2 activity was measured by a COX Fluorescent inhibitor screen assay kit (Cayman Chemical) following the manufacturer's instructions. In both assays, 5 μM of PGE0001 was tested.
Anti-tumor activity
Approximately 1×10 6 SW837 rectal cancer cells or A549 lung cancer cells in log cell growth were resuspended in 0.1 ml phosphate buffered saline and injected subcutaneously (s.c.) into the flanks of female severe combined immunodeficient (SCID) mice. When the tumors reached volumes 100-150 mm 3 , the mice were stratified into groups of 8 animals having approximately equal mean tumor volumes and administration of compound PGE0001 suspended in 0.1% Tween-20 in water was started at a dose of 200 mg/kg (for SW837) or 100 mg/kg (for A549) i.p. daily for 5 days. The animals were weighed weekly and tumor diameters measured twice weekly at right angles (d short and d long ) with electronic calipers and converted to volume by the formula volume ¼ ðd short Þ 2 Â ðd long Þ=2 [41] . When the tumor volume reached ≥2,000 mm 3 or became necrotic, the animals were euthanized. Anti-tumor effects are presented as%T/C (treatment-to-control ratio), where T and C represent the means of tumor volumes of the treatment and control mice, respectively [42] .
Pharmacokinetic and pharmacodynamic studies
All studies involving animals were conducted in accordance with U.S. Public Health Service/U.S. Department of Agriculture guidelines and experimental protocols were approved by The University of Arizona Institutional Animal Care and Use Committee (IACUC). For pharmacokinetic studies, C57BL/6 mice received a single i.p. dose of compound PGE0001 at 200 mg/kg suspended in 0.1% Tween-20 in 0.9% NaCl. Mice were sacrificed after 30 min, 1, 2, 4, 6, 8, 14 and 24 h, blood was collected into heparinized tubes, and plasma was stored frozen at −80°C. Plasma levels of compound PGE0001 were measured by reverse-phase high-pressure liquid chromatography. For pharmacodynamic studies, SCID mice received a single i.p. dose of compound PGE0001 of 100 mg/kg. Mice were killed after 30 min, 1, 3, 5 or 24 h; blood was collected and indomethacin (Cayman Chemical) was added to the collection tubes immediately after drawn (final concentration 10 μg/ml). Serum was then collected and stored frozen at −80°C. Serum levels of PGE 2 were measured by an enzyme immunoassay.
Statistical analyses
Data are presented as mean ± S.D. Statistical analyses (Student's two-tailed t-tests) were performed using Stata software (Stata Corporation, College Station, TX).
Results
Discovery of an aminothiazole scaffold that binds to mPGES-1
We performed an in silico screen on the~312,410 compound ChemBridge diversity library to identify novel mPGES-1 inhibitors. From the database searches and molecular docking, 13 compounds were identified as "potential hits" (Table 1 ). These hits were ranked according to their FlexiDock scores. These scores can be correlated to the binding of these compounds to the protein target (Table 1) . Indeed, equilibrium dissociation constant K D of each compound was measured using expressed 6xHis-tagged mPGES-1 in E. coli and SPR spectroscopy. Among the 13 hits, 7 compounds presented the aminothiazole scaffold. They are 5807166 (#2 in Table 1 ), PGE0001 (#3), 5724933 (#4), 5935487 (#5), 7882458 (#6), 5662444 (#7), and 5933870 (#12). However, only PGE0001 and #7 were able to bind directly to mPGES-1 as revealed by their low K D .
Representative dose response curves are shown in , and an off rate of
). These curves demonstrated a slow "on" and slow "off" rate binding pattern of the compound to mPGES-1. Molecular modeling of aminothiazole compounds with the protein showed extended interactions with the active site residues of mPGES-1. Thus, from the modeling studies, it is postulated that compound PGE0001 interacts in an extended conformation with the protein (Fig. 1a) (Fig. 1b) .
Biological activities of the compounds in cancer cells
In order to determine the effect of the 13 compounds on PGE 2 production, HCA-7 colon cancer cells which express both COX-2 and mPGES-1 [18] were treated with the compounds at 1 μM and stimulated with IL-1β. The relative PGE 2 levels in the culture media in comparison with vehicle (DMSO) control are listed in Table 1 . Out of 13 compounds identified, 6 compounds (PGE0001, #2, #4, #5, #7, and #9) inhibited IL-1β induced PGE 2 production by more than 50%. However, the PGE 2 reduction activity of #2, #4, and #5 was attributed to COX-2 inhibition. Indeed, these compounds were tested for COX-2 inhibition in vitro (Table 1 ). Compound # 6 inhibited COX-2 enzyme activity by~78% at 5 μM. However, other aminothiazoles showed only 30-60% inhibition of COX-2 at 5 μM. Both PGE0001 and #7, showed low K D value, reduced IL-1β induced PGE 2 production by~80% and~60%, respectively and only inhibited COX-2 activity by~30%, which may represent an insignificant effect on COX-2.
Hence, PGE0001 and #7 were identified as our selective lead molecules. In order to further characterize PGE0001 in colon and lung cancer cells, we measured the effects of increasing concentrations of the compound on cytokineinduced PGE 2 production. In colon cancer cells lines (HCA-7 and HT-29) and A549 lung cancer cells, mPGES-1 expression is induced by IL-1β (Fig. 2a and [43] ). On the contrary, SW837 cells were shown to express high levels of mPGES-1 constitutively (Fig. 3a) . The treatment of the cells with increasing concentrations of PGE0001 decreased IL-1β-induced PGE 2 production in HCA-7 and A549 cells in a dose dependent manner with an EC 50 =0.29±0.08 μM and EC 50 =0.32±0.09 μM, respectively (Fig. 2b) . PGE0001 also exhibited similar activity in two other colorectal cancer cell lines SW837 (EC 50 =0.76±0.14 μM) and in HT-29 (EC 50 =0.87±0.39 μM) (data not shown). Celecoxib (COX-2 inhibitor) and MK-886 (dual inhibitor of mPGES-1 and 5-lipoxygenase activating protein) were tested at 1 μM and used as comparable controls. The overall levels of COX-2 and mPGES-1 expression did not change in the presence of the compounds (data not shown), hence it was concluded that the changes in PGE 2 production were due to the overall inhibition of the pathway.
In order to distinguish COX-2 inhibition versus PGE 2 synthase inhibition, we performed a de novo PGE 2 synthesis assay as described recently by Mbalaviele et al. [40] . Cells were pre-treated with compounds, and then induced with arachidonic acid for 10 min. PGE 2 and 6-keto PGF 1α (metabolite of PGI 2 ) levels were measured in the media using separate EIA kits (Fig. 2c) . In resting HCA-7 cells (left panel, Fig. 2c ) or IL-1β-stimulated A549 cells (right panel, Fig. 2c ) cells, Celecoxib inhibited both PGE 2 and 6-keto PGF 1α de novo synthesis, whereas MK-886 reduced PGE 2 specifically. A mixed effect of PGE0001 was observed and neither PGE 2 nor 6-keto PGF 1α was greatly decreased. Finally, PGE0001 slightly inhibited cellular proliferation of colon cancer cell lines as measured by a MTT assay and caused~20% of apoptosis with 20 μM of PGE0001 as measured by an acridine-orange stain. PGE0001 induced PARP cleavage as well in these cells (data not shown).
Effects of PGE0001 on tumor growth
The effects of PGE0001 were evaluated on xenografts mouse tumor growth. SW837 rectal cancer cell line has a constitutive over-expression of mPGES-1 reflecting at best clinical observations where mPGES-1 is constitutively over-expressed in more than 80% of human colorectal cancers [44] (Fig. 3a-c) . Mice were inoculated with 1×10 6 SW837 cells subcutaneously in the right flank. When the average tumor volume reached~150 mm 3 , mice were randomly pair-matched into 8 mice per group: a control Table 2 and Fig. 3b . Compound PGE0001 exhibited a significant anti-tumor activity in SW837 xenografts with T/C 39.9% (p<0.05). We also tested the anti-tumor effect of PGE0001 in the A549 xenograft mouse model where mice were treated with 2 cycles of PGE0001 (100 mg/kgi.p. for 5 days). As shown in Table 2 and Fig. 3c , the tumor burden of the PGE0001-treated group was lower. The T/C was 37.9% (p<0.05). Significance was achieved for the compound after the second cycle of drug treatment until the end of the experiment as compared to controls. Finally, the compound also exhibited anti-tumor activity in HCA-7 colon cancer xenografts at 200 mg/kg for 5 days (Table 2 ). However, the significance was only achieved right after the treatment period ended and tumor growth resumed at its original rate when the drug was removed.
Early pharmacokinetic studies showed that plasma levels of PGE0001 following i.p. administration to mice at a dose of 200 mg/kg was best described by a two compartment open model (Fig. 3d) . Absorption was rapid, without a lag phase and C max was 5.6 μg/ml was reached within 1 h following dosing. PGE0001 terminal half-life was 7.7 h and plasma clearance was 6.6 l/h/kg with a terminal concentration of 0.1 μg/ml 24 h after dosing. The concentration was calculated to be higher than the EC 50 for PGE 2 reduction in cells. In order to determine the effect of the compound PGE0001 on blood PGE 2 level, mice were injected i.p. with The recombinant 6xHis-human mPGES-1 was loaded on a CM5 chip and the compound was flowed through at a rate 50 μg/min a single dose of PGE0001 (100 mg/kg) and serum samples were collected at different time points for PGE 2 measurements. This dose produced up to 70% inhibition at 1 and 5 h with almost a return to untreated levels by 24 h Fig. 2 Effects of PGE0001 on PGE 2 production in cancer cells. a HCA-7 colon cancer cells (left) and A549 lung cancer cells (right) were stimulated with IL-1β (+) or non-stimulated (− for control). COX-2 and mPGES-1 induction were detected by Western blotting using specific antibodies. β-actin was used as loading control. b Left panel: HCA-7 cells were treated as described above and incubated for 72 h with increasing concentrations of PGE0001 (0.03, 0.1, 0.3, 1, and 3 μM), Celecoxib (1 μM), or MK-886 (1 μM). The release of PGE 2 in the culture media was measured using an enzyme immunoassay kit for PGE 2 detection. Right panel: A549 lung cancer cells were stimulated with IL-1β, incubated for 48 h with increasing concentrations of PGE0001 (0.1, 0.5, 1, and 10 μM), Celecoxib (1 μM) or MK-886
(1 μM). PGE 2 was measured as described. Values are relative and are the means of at least 3 determinations. * p<0.05; ** p<0.01 (Student's t-tests) compared to control stimulated with IL-1β. c HCA-7 cells (left panel) or IL-1β-stimulated A549 cells (right panel) were pre-treated with PGE0001 (10 μM), Celecoxib (10 μM), MK-886 (10 μM) or DMSO as vehicle control for 2 h. The cells were then treated with AA and the media were collected for PGE 2 and 6-keto PGF 1α measurements as described in the Materials and Methods section. Values are relative and are the means of at least 3 determinations±SD. Statistical analysis (Student's t-tests) for PGE 2 levels: * p<0.05; ** p<0.01 compared to the vehicle control. Statistical analysis (Student's t-tests) for 6-keto PGF 1α levels: # p<0.05; ## p<0.01 compared to the vehicle control (Fig. 3e) . These results correlated well with the plasma concentrations of PGE0001 after the single dose. Taken together, in vivo studies demonstrated that PGE0001 reduced serum PGE 2 and exhibited good anti-tumor activity. In order to fully define the mechanism of action for PGE0001, we tested the effects of the compound on mPGES-1, COX-2 and sphingosine kinase-1 (SPHK-1) using cell-free assays (Fig. 4) . Surprisingly, we demonstrated that 20 μM of PGE0001 did not inhibit mPGES-1 (regardless of the protein source) and that 5 μM of PGE0001 did not affect the activity of COX-2 or SPHK-1 in vitro (Fig. 4) . Figure 4a represents the activity of recombinant human mPGES-1 from Cayman Chemical. Similar results were obtained using our recombinant human mPGES-1 (expressed by E. coli, data not shown) as well as membrane preparation from A549 cells (data not shown) according to the published protocol [30] . PGE0001 reduced COX-2 activity by~30% at 5 μM which appears much less significant when compared to Celecoxib, which produced a~90% inhibition of the activity at the same concentration (Fig. 4b) . PGE0001 did not affect SPHK-1 activity (Fig. 4c) .
Discussion
Although there is accumulated evidence supporting the role of mPGES-1 in carcinogenesis [25, 28] , the effect of mPGES-1 deletion on tumorigenesis, at least in gastrointestinal cancer, is still controversial [25, 45] . Pre-clinical tests for mPGES-1 inhibitors have been limited to models of inflammation and pain [46, 47] . To the best of our knowledge, no information about an in vivo anti-tumor activity of mPGES-1 inhibitor has been published. In this study, we used docking models to evaluate the compounds for their interaction with mPGES-1 active site. The FlexiDock scores showed good correlation with K D values (for binding to mPGES-1) measured using SPR technology. Compounds #8, #10, #11, #12, and #13 were hypothesized to bind poorly to mPGES-1 active site were subsequently determined not to bind the protein. These compounds did not inhibit PGE 2 production in the cells. Interestingly, #2, #4, #5 and #6 were predicted to bind better to mPGES-1 but did not bind the target. These compounds reduced PGE 2 production and were subsequently shown to inhibit between~60 to 80% the activity of COX-2 in a cell-free assay. Compound #6 inhibited strongly COX-2 but was not able to reduce PGE 2 production probably due to a poor bioavailability or stability in the cells. Thus, molecular modeling combined with SPR allowed us to focus on PGE0001 and #7, which exhibited a good K D value and the ability to decrease 60 to 80% of PGE 2 production without affecting COX-2 activity as measured in the cell free assay and the de novo PGE 2 synthesis assay. Indeed, no reduction of 6-keto PGF 1α was observed in the presence of PGE0001. PGE0001 exhibited promising anti-tumor activity. PGE 2 production was also inhibited in vivo after a single dose of 100 mg/kg of PGE0001. Maximum inhibition was observed between 30 min to 5 h after administration of PGE0001, with the timing corresponding to its peak plasma concentration. There was also anti-tumor activity with complete cessation of tumor growth and even some regression following the administration of PGE0001 in SW837 colorectal xenografts. Absorption, metabolism, distribution and elimination properties of PGE0001 were predicted that low cardiotoxicity may be expected as evaluated by hERG channel activity (data not shown). Additionally, physicochemical properties such as e Animals were given a second regimen of 5 days.
polar surface area (PSA) and logD were calculated as indicators of cellular permeability and solubility respectively. The values were: tPSA: 33.62 and logD: 5.95, suggesting a high likelihood of the compound passively diffusing into cells and permeating the small intestine cell wall. The compound also has high logD which may indicate poor water solubility. However observations solubility was sufficient in water for accurate biological evaluation. Noteworthy, the compound was well tolerated in animals up to the dose of 200 mg/kg, where a significant anti-tumor activity was observed. Surprisingly, PGE0001 did not inhibit COX-2 nor mPGES-1 activity in vitro sufficiently enough to explain the reduction of cellular PGE 2 production in cancer cells and the in vivo anti-tumor effect observed in mouse xenografts. Interestingly, the chemical structure of PGE0001 is strangely similar to a compound known reported as a SPHK-1 inhibitor [48] . Sphingosine-1 phosphate (S1P), the product of SPHK-1, has been shown to induce COX-2 expression [49] [50] [51] . Therefore, the measured PGE 2 reduction effect of PGE0001 in cancer cells could also result from the inhibition of SPHK-1. However, PGE0001 did not inhibit SPHK-1 activity in vitro when tested in a cell-free assay. Among other possible off-targets that would affect PGE 2 biosynthesis, we have identified two kinases as potential targets. These alternative mechanisms are currently under investigation.
In conclusion, PGE0001 showed binding to the expressed mPGES-1 protein and exhibited in vitro PGE 2 reduction in colorectal and lung cancer cell lines. Although the mechanism of action of such compound may remain to be clarified, its promising anti-tumor activity made it a worthwhile compound to study. Derivatization of one of the aminothiazole compounds may lead to the identification of a novel generation of active small molecules that may represent a good starting point and chemical probe for future anti-cancer studies.
Conflict of interest The authors declare that they have no conflict of interest. Fig. 4 In vitro effects of PGE0001. a mPGES-1 activity was measured as described in the Materials and methods section. PGE0001 and MK-886 (20 μM) were pre-incubated with the enzyme and the remaining activity of mPGES-1 as ng/ml of PGE 2 produced was measured using an EIA kit. b COX-2 activity was measured as described. PGE0001, Celecoxib and MK-886 (5 μM) were pre-incubated with the enzyme and the remaining relative COX-2 enzymatic activity was measured according to the manufacturer's instructions. Control activity (in the presence of DMSO) was reported at 100%. c SPHK-1 activity was measured as described. SPHK-1 inhibitor and PGE0001 (5 μM) were pre-incubated with the enzyme and the remaining relative enzymatic activity was measured. * p<0.05; ** p<0.01 (Student's t-tests)
